Pacific Bio (PACB) – Press Releases
-
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
-
PacBio Grants Equity Incentive Award to New Employee
-
PacBio Announces PureTargetâ„¢ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions
-
PacBio to Present at Upcoming Investor Conferences
-
PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
-
Experiential Marketing Firm VOLO Events Agency Wins Best Event Technology Award for PacBio Product Launch
-
PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale
-
PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024
-
PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions
-
TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors
-
PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively
-
PacBio to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
PacBio Announces the Retirement of David Botstein, Ph.D., from its Board of Directors
-
PacBio to Present at Upcoming Investor Conferences
-
PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders
-
PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partners to PacBio Compatible
-
PacBio Announces Kinnex RNA Kits, Further Scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA Applications
-
PacBio Announces Third Quarter 2023 Financial Results
-
PacBio Announces Appointment of David Meline to Board of Directors
-
PacBio to Report Third Quarter 2023 Financial Results on October 30, 2023
-
PacBio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis
-
PacBio Announces PacBio Capital
-
PacBio Announces Collaboration with Leading Library Preparation Automation Partners
-
PacBio to Present at Upcoming Investor Conferences
-
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
-
PacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)
-
PacBio Announces Second Quarter 2023 Financial Results
-
PacBio Enters into Agreement to Acquire Apton Biosystems to Accelerate the Development of a Next Generation, High Throughput, Short-read Sequencer
-
PacBio Begins Commercialization of the Onso Short-Read Sequencing System
-
PacBio to Report Second Quarter 2023 Financial Results on August 2, 2023
-
PacBio's Revio System Empowers Bioscientia to Scale Long-Read Whole Genome Sequencing and Unravel the Mysteries of Rare Disease
-
PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030
-
PacBio and Radboud University Medical Center Team Up for New Discoveries in Rare Disease Research
-
PacBio Announces the Appointment of Olga Troyanskaya from Princeton University to the Scientific Advisory Board
-
PacBio to Present at Upcoming Investor Conferences
-
PacBio to Present at BofA Securities 2023 Health Care Conference
-
PacBio Announces Record Revenue in First Quarter 2023
-
PacBio to Report First Quarter 2023 Financial Results on May 2, 2023
-
PacBio Announces New Nanobind Extraction Kits to Enable High-Throughput Workflows with Revio and Sequel Systems
-
PacBio and Corteva Agriscience Enable Groundbreaking Plant and Microbial Long-Read Sequencing Workflow on Revio System
-
Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer
-
PacBio Announces a New Informatics Analysis Method for Highly Homologous Genes
-
PacBio To Begin Commercial Shipment of Revio Systems
-
PacBio to Present at Cowen's 43rd Annual Health Care Conference
-
PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results
-
PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions
-
PacBio to Report Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023
-
Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year"
Back to PACB Stock Lookup